HLB Genex, Inc. Logo

HLB Genex, Inc.

Develops custom enzymes & microbiome solutions for diagnostics, nutrition, and cosmetic markets.

187420 | KO

Overview

Corporate Details

ISIN(s):
KR7187420005
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노1로 65(관평동), 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

HLB Genex, Inc. is a biotechnology company specializing in the development and production of customized enzymes and microbiome-based solutions. The company leverages proprietary R&D platforms, including Microbial Surface Display Technology for high-throughput screening and Recombinant Protein Expression for scalable manufacturing. Its product portfolio consists of industrial special enzymes, such as Lactase, Catalase, and Proteinase K used in molecular diagnostics, and bio-healthcare ingredients like Vitamin K2 and Phytosphingosine for nutritional and cosmetic applications. HLB Genex is also actively engaged in the research and development of microbiome therapeutics by discovering and engineering effector molecules from beneficial microorganisms.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-20 00:00
Capital/Financing Update
주권관련사채권의취득결정
Korean 37.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-07-07 00:00
Share Issue/Capital Change
전환가액의조정
Korean 12.7 KB
2025-07-07 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 13.3 KB
2025-06-30 00:00
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
Korean 18.3 KB
2025-06-26 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.6 KB
2025-06-10 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-05-21 00:00
M&A Activity
타법인주식및출자증권취득결정
Korean 25.4 KB
2025-05-13 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.8 MB
2025-05-12 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-05-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-04-30 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 240.1 KB
2025-04-17 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 239.0 KB
2025-04-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-04-15 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 239.0 KB

Automate Your Workflow. Get a real-time feed of all HLB Genex, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HLB Genex, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HLB Genex, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.